Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations

Special Issue

Abstract

Psychopharmacotherapy should now be regulated in the sense of evidence-based medicine, as is the case in other areas of clinical treatment in medicine. In general this is a meaningful development, which principally will have a positive impact on routine health care in psychiatry. But several related problems should not be ignored. So far consensus on an internationally accepted evidence graduation could not be reached due to several difficulties related to this. For example, focussing on the results of meta-analyses instead of considering relevant single studies results in a decision-making logic which is in conflict with the rationale applied by drug authorities in the licensing process. Another example is the relevance of placebo-controlled trials: if randomized placebo-controlled phase-III studies are prioritized in the evidence grading, the evidence possibly deviates too far from the conditions of routine clinical care due to the special selection of patients in those studies. However, a grading primarily based on active comparator trials could lead to wrong conclusions about efficacy. This concerns especially the so-called “effectiveness” studies and other forms of phase-IV studies with their less restrictive methodological rigidity. Attempts to regulate psychopharmacotherapy in the sense of evidence-based medicine come closer to their limits the more complex the clinical situation and the respective decision-making logic are. Even in times of evidence-based medicine a large part of complex clinical decision-making in psychopharmacotherapy still relies more on clinical experience and a consensus on clinical experience, traditions and belief systems than on results of efficacy oriented phase-III and effectiveness-oriented phase-IV clinical studies.

Keywords

Evidence-based Evidence grading Psychopharmacotherapy Guidelines 

References

  1. 1.
    Adli M, Rush J, Möller HJ, Bauer M (2003) Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 36 (Suppl 3):S222–S229PubMedGoogle Scholar
  2. 2.
    Adli M, Bauer M, Rush AJ (2006) Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 59:1029–1038PubMedCrossRefGoogle Scholar
  3. 3.
    Altman DG, Andersen PK (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319:1492–1495PubMedGoogle Scholar
  4. 4.
    American Association of Clinical Endocrinologists, American Diabetes Association, American Psychiatric Association, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601CrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association APA Guideline Development Process (2006) http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm
  6. 6.
    Antes G (2004) The evidence base of clinical practice guidelines, health technology assessments and patient information as a basis for clinical decision-making. Z Ärztl Fortbild Qualitätssich 98:180–184PubMedGoogle Scholar
  7. 7.
    Ascher-Svanum H, Zhu B, Faries D, Ernst FR (2004) A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 3:11PubMedCrossRefGoogle Scholar
  8. 8.
    Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J (2006) Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8PubMedCrossRefGoogle Scholar
  9. 9.
    Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D et al (2004) Grading quality of evidence and strength of recommendations. BMJ 19:1490Google Scholar
  10. 10.
    Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, Liberati A, O’Connell D, Oxman AD, Phillips B et al (2004) Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 4:38PubMedCrossRefGoogle Scholar
  11. 11.
    Atkins D, Briss PA, Eccles M, Flottorp S, Guyatt GH, Harbour RT, Hill S, Jaeschke R, Liberati A, Magrini N et al (2005) Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 5:25PubMedCrossRefGoogle Scholar
  12. 12.
    Baghai TC, Möller HJ, Rupprecht R (2006) Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des 12:503–515PubMedCrossRefGoogle Scholar
  13. 13.
    Baldwin DS (2006) Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes? CNS Spectr 11:34–39PubMedGoogle Scholar
  14. 14.
    Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253:22–28PubMedCrossRefGoogle Scholar
  15. 15.
    Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety (2003) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171–199Google Scholar
  16. 16.
    Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety (2008) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312Google Scholar
  17. 17.
    Bateman A, Fonagy P (1999) Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 156:1563–1569PubMedGoogle Scholar
  18. 18.
    Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43Google Scholar
  19. 19.
    Bauer M, Whybrow PC, Angst J (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3:69–86PubMedCrossRefGoogle Scholar
  20. 20.
    Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Unipolar Depressive Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8:67–104Google Scholar
  21. 21.
    Bauer M, Tharmanathan P, Volz HP, Möller HJ, Freemantle N (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259:172–185PubMedCrossRefGoogle Scholar
  22. 22.
    Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR (2009) Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol 23:574–591Google Scholar
  23. 23.
    Bottlender R, Rudolf D, Strauss A, Moller HJ (1998) Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. Eur Psychiatry 248:296–300Google Scholar
  24. 24.
    Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, Tyrer P (2000) Framework for design and evaluation of complex interventions to improve health. BMJ 321:694–696PubMedCrossRefGoogle Scholar
  25. 25.
    Carpenter WT (2001) Evidence-based treatment for first-episode schizophrenia? Am J Psychiatry 158:1771–1773PubMedCrossRefGoogle Scholar
  26. 26.
    Cartabellotta A, Minella C, Bevilacqua L, Caltagirone P (1998) Evidence-based medicine. 3. Systematic reviews: a tool for clinical practice, permanent education and health policy decisions. Italian Group on Evidence-Based Medicine-GIMBE. Recenti Prog Med 89:329–337PubMedGoogle Scholar
  27. 27.
    Cartabellotta A, Montalto G, Notarbartolo A (1998) Evidence-based medicine. How to use biomedical literature to solve clinical problems. Italian Group on Evidence-Based Medicine-GIMBE. Minerva Med 89:105–115PubMedGoogle Scholar
  28. 28.
    Catty J, Burns T, Comas A (2001) Day centres for severe mental illness. Cochrane Database Syst Rev: CD001710Google Scholar
  29. 29.
    Chilvers R, Macdonald GM, Hayes AA (2002) Supported housing for people with severe mental disorders. Cochrane Database Syst Rev: CD000453Google Scholar
  30. 30.
    Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758PubMedCrossRefGoogle Scholar
  31. 31.
    Citrome L (2007) Show me the evidence: using number needed to treat. South Med J 100:881–884PubMedGoogle Scholar
  32. 32.
    Clark W, Mucklow J (1998) Gathering and weighing the evidence. In: Panton R, Chapman S (eds) Medicines Management. BMJ Books and Pharmaceutical Press, London, pp 59–74Google Scholar
  33. 33.
    Committee for Proprietary Medicinal Products (CPMP) (2002) Note for guidance on clinical investigation of medicinal products in the treatment of depression. http://www.emea.eu.int
  34. 34.
    Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic Combinations vs Monotherapy in Schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35:443–457PubMedCrossRefGoogle Scholar
  35. 35.
    Craig JC, Irwig LM, Stockler MR (2001) Evidence-based medicine:useful tools for decision making. MJA 174:248–253PubMedGoogle Scholar
  36. 36.
    Crowther R, Marshall M, Bond G, Huxley P (2003) Vocational rehabilitation for people with severe mental illness (Cochrane Review) [computer program]. In: The Cochrane library, issue 3. Update Software, OxfordGoogle Scholar
  37. 37.
    Cuffel B, Martin J, Joyce AT, Boccuzzi SJ, Loebel A (2006) Lipid and glucose monitoring during atypical antipsychotic treatment: effects of the 2004 ADA/APA consensus statement. Poster presented at the 2006 APA Annual Meeting, Toronto, Canada, 20–25 May 2006Google Scholar
  38. 38.
    Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564PubMedCrossRefGoogle Scholar
  39. 39.
    Delaney B (2006) Is society losing control of the medical research agenda? BMJ 332:1063–1064PubMedCrossRefGoogle Scholar
  40. 40.
    Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J et al (2004) Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65:312–321PubMedGoogle Scholar
  41. 41.
    Eccles M, Mason J (2001) How to develop cost-conscious guidelines. Health Technol Assess 5(16):1–69PubMedGoogle Scholar
  42. 42.
    Eccles M, Grimshaw J, Campbell M, Ramsay C (2003) Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care 12:47–52PubMedCrossRefGoogle Scholar
  43. 43.
    Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA (2006) Effectiveness of switching antipsychotic medications. Am J Psychiatry 163:2090–2095PubMedCrossRefGoogle Scholar
  44. 44.
    Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia (2005) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132–191Google Scholar
  45. 45.
    Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5–40PubMedCrossRefGoogle Scholar
  46. 46.
    Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF et al (2003) Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26:457–494PubMedCrossRefGoogle Scholar
  47. 47.
    Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF et al (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161–1172PubMedCrossRefGoogle Scholar
  48. 48.
    Feinstein AR (1995) Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48:71–79PubMedCrossRefGoogle Scholar
  49. 49.
    Fritze J, Möller HJ (2001) Design of clinical trials of antidepressants. Should a placebo control arm be included? CNS Drugs 15:755–764PubMedCrossRefGoogle Scholar
  50. 50.
    Fulford KWM (2004) Facts/values: ten principles of value-based medicine. In: Radden J (ed) The philosophy of psychiatry: a companion. New York, Oxford University Press, pp 205–236Google Scholar
  51. 51.
    Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS (2005) Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 187:248–255PubMedCrossRefGoogle Scholar
  52. 52.
    Geddes J, Freemantle N, Harrison P, Bebbington P, for the National Schizophrenia Guideline Development Group (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376Google Scholar
  53. 53.
    Geddes JR, Freemantle N, Mason J, Eccles M, Boynton J (2000) SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev: CD001851Google Scholar
  54. 54.
    Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4–9PubMedCrossRefGoogle Scholar
  55. 55.
    Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L (1999) Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. Harv Rev Psychiatry 7:1–28PubMedCrossRefGoogle Scholar
  56. 56.
    Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004) Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:1537–1547PubMedCrossRefGoogle Scholar
  57. 57.
    Gonzalez DD (2001) From evidence-based medicine to medicine-based evidence. An Esp Pediatr 55:429–439Google Scholar
  58. 58.
    Gorouhi F, Jafarian S, Firooz A (2007) Reporting of number needed to treat and its difficulties. J Am Acad Dermatol 57:729–730PubMedCrossRefGoogle Scholar
  59. 59.
    Gray SH (2002) Evidence-based psychotherapeutics. J Am Acad Psychoanal 30:3–16PubMedCrossRefGoogle Scholar
  60. 60.
    Gray GE, Pinson LA (2003) Evidence-based medicine and psychiatric practice. Psychiatr Q 74:387–399PubMedCrossRefGoogle Scholar
  61. 61.
    Greenhalgh T (2006) How to read a paper: the basics of evidence based medicine, 3rd edn. BMJ Books/Blackwell, LondonGoogle Scholar
  62. 62.
    Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, Eccles MP, Matowe L, Shirran L et al (2004) Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 8:iii–iv, 1–72Google Scholar
  63. 63.
    Grimshaw J, Eccles M, Thomas R, MacLennan G, Ramsay C, Fraser C, Vale L (2006) Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966–1998. J Gen Intern Med 21(Suppl 2):S14–S20PubMedGoogle Scholar
  64. 64.
    Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ (2002) World Federation of Societies of Biological Psychiary (WFSBP) guidelines for biological treatment of bipolar disorders, Part I: treatment of bipolar depression. World J Biol Psychiatry 3:115–124PubMedCrossRefGoogle Scholar
  65. 65.
    Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ (2003) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part II: treatment of mania. World J Biol Psychiatry 4:5–13PubMedCrossRefGoogle Scholar
  66. 66.
    Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ (2004) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part III: maintenance treatment. World J Biol Psychiatry 5:120–135PubMedCrossRefGoogle Scholar
  67. 67.
    Grunze H, Vieta E, Guy M, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S, WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 10:85–116PubMedCrossRefGoogle Scholar
  68. 68.
    Gupta M (2007) Does evidence-based medicine apply to psychiatry? Theor Med Bioeth 28:103–120PubMedCrossRefGoogle Scholar
  69. 69.
    Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:174–181PubMedCrossRefGoogle Scholar
  70. 70.
    Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, Schunemann H (2006) An emerging consensus on grading recommendations? ACP J Club 144:A8–A9PubMedGoogle Scholar
  71. 71.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926PubMedCrossRefGoogle Scholar
  72. 72.
    Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008) Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59:1121–1130PubMedCrossRefGoogle Scholar
  73. 73.
    Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ et al (2003) The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 107:222–232PubMedCrossRefGoogle Scholar
  74. 74.
    Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D et al (2007) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17:235–244PubMedCrossRefGoogle Scholar
  75. 75.
    Hegerl U, Plattner A, Moller HJ (2004) Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci 254:99–107PubMedCrossRefGoogle Scholar
  76. 76.
    Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I et al (2009) Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115:439–449PubMedCrossRefGoogle Scholar
  77. 77.
    Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185–194PubMedCrossRefGoogle Scholar
  78. 78.
    Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J et al (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63:826–837PubMedGoogle Scholar
  79. 79.
    Holsboer F (2008) How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 8:638–646CrossRefGoogle Scholar
  80. 80.
    Jadad AR, Phil D, Cook DJ (1998) Methodology and reports of systematic reviews and meta-analyses-acomparison of Cochrane reviews with articles published in paper-based journals. JAMA 280:278–280PubMedCrossRefGoogle Scholar
  81. 81.
    Jiang Q, Ahmed S (2009) An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder. Ann Gen Psychiatry 8:4PubMedCrossRefGoogle Scholar
  82. 82.
    Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, Frodl T, Mavrogiorgou P, Hegerl U (2007) Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. J Clin Psychiatry 68:1206–1212PubMedCrossRefGoogle Scholar
  83. 83.
    Kallert TW (2005) [Is mental health services research in need of randomised controlled trials?] Braucht psychiatrische Versorgungsforschung randomisierte kontrollierte Studien? Psychiatr Prax 32:375–377PubMedCrossRefGoogle Scholar
  84. 84.
    Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24:62–67PubMedGoogle Scholar
  85. 85.
    Kane JM, Honigfeld G, Singer J, Meltzer HY (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 48:789–796Google Scholar
  86. 86.
    Kawamura T, Tamakoshi A, Wakai K, Ohno Y (1999) Evidence-based medicine and ‘The Cochrane Collaboration’. Nippon Koshu Eisei Zasshi 46:498–506PubMedGoogle Scholar
  87. 87.
    Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:260–268CrossRefGoogle Scholar
  88. 88.
    Kjaergard LL, Is-Nielsen B (2002) Association between competing interests and authors’ conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 325:249PubMedCrossRefGoogle Scholar
  89. 89.
    Klein DF (2000) Flawed meta-analyses comparing psychotherapy with pharmacotherapy. Am J Psychiatry 157:1204–1211PubMedCrossRefGoogle Scholar
  90. 90.
    Kunz R, Vist G, Oxman A (2007) Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 18(2):MR000012Google Scholar
  91. 91.
    Lehman AF, Steinwachs DM (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24:1–10PubMedGoogle Scholar
  92. 92.
    Leichsenring F, Rabung S, Leibing E (2004) The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 61:1208–1216PubMedCrossRefGoogle Scholar
  93. 93.
    Lerer B, Macciardi F (2002) Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 5:255–275PubMedCrossRefGoogle Scholar
  94. 94.
    Leucht S (2004) Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 7:S15–S20PubMedCrossRefGoogle Scholar
  95. 95.
    Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589PubMedCrossRefGoogle Scholar
  96. 96.
    Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447PubMedCrossRefGoogle Scholar
  97. 97.
    Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41PubMedCrossRefGoogle Scholar
  98. 98.
    Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Lobos CA, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152–163PubMedCrossRefGoogle Scholar
  99. 99.
    Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB (2005) Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30:445–460PubMedCrossRefGoogle Scholar
  100. 100.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRefGoogle Scholar
  101. 101.
    Linden M (2005) Leitlinien und die Psychologie medizinischer Entscheidungsprozesse bei der Behandlung depressiver Erkrankungen [Guidelines and the psychology of medical decision making in the treatment of depressive disorders]. Fortschr Neurol Psychiat 73:249–258PubMedCrossRefGoogle Scholar
  102. 102.
    Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N (2006) Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 63:757–766PubMedCrossRefGoogle Scholar
  103. 103.
    Lohr KN (2004) Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 16:9–18PubMedCrossRefGoogle Scholar
  104. 104.
    Maier W, Möller HJ (2005) Metaanalyses—highest level of empirical evidence? Eur Arch Psychiatry Clin Neurosci 255:369–370PubMedCrossRefGoogle Scholar
  105. 105.
    Maier W, Möller HJ (2008) Meta-analyses: a method to maximize the evidence from clinical studies? Eur Arch Psychiatry Clin Neurosci (in preparation)Google Scholar
  106. 106.
    Manser R, Walters EH (2001) What is evidence-based medicine and the role of the systematic review: the revolution coming your way. Monaldi Arch Chest Dis 56:33–38PubMedGoogle Scholar
  107. 107.
    Marshall M, Lockwood A (2003) Assertive communication treatment for people with severe mental disorder (Cochrane Review) [computer program]. In: The Cochrane library, issue 3. Update Software, OxfordGoogle Scholar
  108. 108.
    Marshall M, Gray A, Lockwood A, Green R (2003) Case management for people with severe mental disorders (Cochrane Review) [computer program]. Update Software, OxfordGoogle Scholar
  109. 109.
    Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D (2003) Day hospital versus admission for acute psychiatric disorders. Cochrane Database Syst Rev: CD004026Google Scholar
  110. 110.
    McCabe C, Dixon S (2000) Testing the validity of cost-effectiveness models. Pharmacoeconomics 17:501–513PubMedCrossRefGoogle Scholar
  111. 111.
    McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26:733–744PubMedCrossRefGoogle Scholar
  112. 112.
    Melander H, Ahlqvist-rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173PubMedCrossRefGoogle Scholar
  113. 113.
    Melander H, Salmonson T, Abadie E, van Zwieten-Boot B (2008) A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623–627PubMedCrossRefGoogle Scholar
  114. 114.
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354:1896–1900PubMedCrossRefGoogle Scholar
  115. 115.
    Möller HJ (2000) State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 1:204–214PubMedCrossRefGoogle Scholar
  116. 116.
    Möller HJ (2006) Ethical aspects of publishing. World J Biol Psychiatry 7:66–69PubMedCrossRefGoogle Scholar
  117. 117.
    Möller HJ (2008) Do effectiveness (“real world”) studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 258:257–270PubMedCrossRefGoogle Scholar
  118. 118.
    Möller HJ (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455PubMedCrossRefGoogle Scholar
  119. 119.
    Möller HJ (2009) Declaration of conflicts of interest in scientific publications. World J Biol Psychiatry 10:2–5 EditorialPubMedCrossRefGoogle Scholar
  120. 120.
    Möller HJ (2009) Standardised rating scales in Psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 10:6–26PubMedCrossRefGoogle Scholar
  121. 121.
    Möller HJ, Grunze H (2000) Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 250:57–68PubMedCrossRefGoogle Scholar
  122. 122.
    Möller HJ, Grunze H, Broich K (2006) Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci 256:1–16PubMedCrossRefGoogle Scholar
  123. 123.
    Möller HJ, Langer S, Schmauss M (2007) Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry 40:53–57PubMedCrossRefGoogle Scholar
  124. 124.
    Möller HJ, Baldwin D, Goodwin G, Kasper S, Okasha A, Stein DJ, Tandon R, Versiani M (2008) Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 258:3–23PubMedCrossRefGoogle Scholar
  125. 125.
    Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME (2008) Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 63:424–434PubMedCrossRefGoogle Scholar
  126. 126.
    NICE National Institute for Health and Clinical Excellence Anxiety (amended): Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. (2007) CG22Google Scholar
  127. 127.
    Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G et al (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519–1530PubMedCrossRefGoogle Scholar
  128. 128.
    O’Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D et al (2005) Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 23:529–536PubMedCrossRefGoogle Scholar
  129. 129.
    Ollenschlager G, Berenbeck C, Low A, Stobrawa F, Kolkmann FW (2002) The National Program for disease management—guidelines under the auspices of the German Medical Association—a method report. Z Arztl Fortbild Qualitatssich 96:545–548PubMedGoogle Scholar
  130. 130.
    Patsopoulos NA, Ioannidis JP, Analatos AA (2006) Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 332:1061–1064PubMedCrossRefGoogle Scholar
  131. 131.
    Pilling S, Price K (2006) Developing and implementing clinical guidelines: lessons from the NICE schizophrenia guideline. Epidemiol Psichiatr Soc 15:109–116PubMedGoogle Scholar
  132. 132.
    REJr Kelly, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A et al (2006) Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med 36:1647–1656CrossRefGoogle Scholar
  133. 133.
    Riedel M, Strassnig N, Müller N, Zwack P, Möller HJ (2005) How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255:143–148PubMedCrossRefGoogle Scholar
  134. 134.
    Rush AJ (2007) STAR*D: What have we learned? Am J Psychiatry 164:201–204PubMedCrossRefGoogle Scholar
  135. 135.
    Rush JA, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K et al (2003) Texas Medication Algorithm Project, Phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 64:357–369PubMedCrossRefGoogle Scholar
  136. 136.
    Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM et al (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142PubMedCrossRefGoogle Scholar
  137. 137.
    Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917PubMedCrossRefGoogle Scholar
  138. 138.
    Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF et al (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242PubMedCrossRefGoogle Scholar
  139. 139.
    Sackett DL (2000) Evidence-based medicine: how to practice and teach EBM. Churchill Livingstone, New YorkGoogle Scholar
  140. 140.
    Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312:71–72PubMedGoogle Scholar
  141. 141.
    Sheehan DV, Burnham DB, Iyengar MK, Perera P, for the Paxil CR Panic Disorder Study Group (2005) Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 66:34–40Google Scholar
  142. 142.
    Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ (2008) Differences in medication adherence and healthcare resource utilization patterns. older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 22:963–973PubMedCrossRefGoogle Scholar
  143. 143.
    Stauffer V, Karagianis J, Sutton V, Ascher-Svanum H, Treuer T, Silva de Lima M, Ball T, Poole-Hoffmann V, Tohen M (2008) Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in randomized, blinded trials comparing olanzapine to other atypical antipsychotics for treatment of schizophrenia. Clin Schizophr Relat Psychoses: 136–146Google Scholar
  144. 144.
    Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53:1119–1129PubMedCrossRefGoogle Scholar
  145. 145.
    Stone JM, Davis JM, Leucht S, Pilowsky LS (2009) Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs—an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 35:789–797PubMedCrossRefGoogle Scholar
  146. 146.
    Stroup TC (2007) Heterogeneity of treatment effects in schizophrenia. Am J Med 120:526–531CrossRefGoogle Scholar
  147. 147.
    Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK, For the CATIE Investigators (2009) Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107: 1–12Google Scholar
  148. 148.
    Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA (2008) What CATIE found: results from the schizophrenia trial. Psychiatr Serv 59:500–506PubMedCrossRefGoogle Scholar
  149. 149.
    Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Möller HJ et al (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100:20–38PubMedCrossRefGoogle Scholar
  150. 150.
    Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B et al (2004) Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 61:669–680PubMedCrossRefGoogle Scholar
  151. 151.
    Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM et al (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252PubMedCrossRefGoogle Scholar
  152. 152.
    Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40PubMedCrossRefGoogle Scholar
  153. 153.
    Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publications of antidepressant trials and its influence on apparent efficacy. N Eng J Med 358:252–260CrossRefGoogle Scholar
  154. 154.
    Wampold BE, Minami T, Baskin TW, Callen TS (2002) A meta-(re)analysis of the effects of cognitive therapy versus ‘other therapies’ for depression. J Affect Disord 68:159–165PubMedCrossRefGoogle Scholar
  155. 155.
    Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR (2007) The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 9:449–459PubMedCrossRefGoogle Scholar
  156. 156.
    Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA (2006) Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 188:410–415PubMedCrossRefGoogle Scholar
  157. 157.
    Yank V, Rennie D, Bero LA (2007) Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 335:1202–1205PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of PsychiatryLudwig-Maximilians-UniversityMunichGermany
  2. 2.Department of PsychiatryUniversity of BonnBonnGermany

Personalised recommendations